Next Article in Journal
Analyzing Zone-Based Registration Using a Three Zone System: A Semi-Markov Process Approach
Next Article in Special Issue
Editorial on Special Issue “Tuberculosis Drug Discovery and Development 2019”
Previous Article in Journal
Comparison of Capillary Flow Porometry (CFP) and Liquid Extrusion Porometry (LEP) Techniques for the Characterization of Porous and Face Mask Membranes
Previous Article in Special Issue
Multi-Omics Technologies Applied to Tuberculosis Drug Discovery
Open AccessReview

Two Decades of TB Drug Discovery Efforts—What Have We Learned?

1
Pharmaron Beijing Co., Ltd., 6, Taihe Road, BDA, Beijing 100176, China
2
Foundation for Neglected Disease Research [FNDR], Plot 20A, KIADB Industrial Area, Doddaballapur, Bengaluru 561203, India
3
Gangagen Biotechnologies P Ltd., #12, 5th Cross, Raghavendra Layout, Tumkur Road, Yeshwantpur, Bengaluru 560022, India
*
Author to whom correspondence should be addressed.
Appl. Sci. 2020, 10(16), 5704; https://doi.org/10.3390/app10165704
Received: 3 May 2020 / Revised: 4 August 2020 / Accepted: 11 August 2020 / Published: 17 August 2020
(This article belongs to the Special Issue Tuberculosis Drug Discovery and Development 2019)
After several years of limited success, an effective regimen for the treatment of both drug-sensitive and multiple-drug-resistant tuberculosis is in place. However, this success is still incomplete, as we need several more novel combinations to treat extensively drug-resistant tuberculosis, as well newer emerging resistance. Additionally, the goal of a shortened therapy continues to evade us. A systematic analysis of the tuberculosis drug discovery approaches employed over the last two decades shows that the lead identification path has been largely influenced by the improved understanding of the biology of the pathogen Mycobacterium tuberculosis. Interestingly, the drug discovery efforts can be grouped into a few defined approaches that predominated over a period of time. This review delineates the key drivers during each of these periods. While doing so, the author’s experiences at AstraZeneca R&D, Bangalore, India, on the discovery of new antimycobacterial candidate drugs are used to exemplify the concept. Finally, the review also discusses the value of validated targets, promiscuous targets, the current anti-TB pipeline, the gaps in it, and the possible way forward. View Full-Text
Keywords: tuberculosis; Mycobacterium tuberculosis; drug discovery; drug development; target-based screening; phenotypic screening; antituberculosis agents; antimycobacterial; anti-TB drug pipeline; privileged targets; promiscuous targets; lead generation tuberculosis; Mycobacterium tuberculosis; drug discovery; drug development; target-based screening; phenotypic screening; antituberculosis agents; antimycobacterial; anti-TB drug pipeline; privileged targets; promiscuous targets; lead generation
Show Figures

Figure 1

MDPI and ACS Style

Bandodkar, B.; Shandil, R.K.; Bhat, J.; Balganesh, T.S. Two Decades of TB Drug Discovery Efforts—What Have We Learned? Appl. Sci. 2020, 10, 5704.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop